Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.

about

Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Metal complexes in cancer therapy - an update from drug design perspective.An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent.

P2860

Q36086603-35CF0F9B-85D0-4204-A353-B4884B5FE60D Q38692975-8D609031-66D3-428F-BF2D-2BEC8BF1C81A Q41015328-BFC5E3EC-1CE7-40EC-AD39-C9528645B0FD

P2860

Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.

Item

http://www.wikidata.org/entity/Q40737623

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Albumin binding and ligand-exc ...... ermined by ENDOR spectroscopy.

@en

type

Item

label

Albumin binding and ligand-exc ...... ermined by ENDOR spectroscopy.

@en

prefLabel

Albumin binding and ligand-exc ...... ermined by ENDOR spectroscopy.

@en

P1476

Albumin binding and ligand-exc ...... ermined by ENDOR spectroscopy.

@en

P2093

Charles J Walsby

http://www.w3.org/2001/XMLSchema#string

Michael I Webb

http://www.w3.org/2001/XMLSchema#string

P2860

The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins

Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu

Investigating the ruthenium metalation of proteins: X-ray structure and Raman microspectroscopy of the complex between RNase A and AziRu

Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.

Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliu

Impact of albumin on drug delivery--new applications on the horizon.

Ruthenium-based chemotherapeutics: are they ready for prime time?

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

P304

17482-17493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C5DT02021B

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26174110

http://www.w3.org/2001/XMLSchema#string

Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.

about

P2860

P2860

Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698